HLA-A*2402-restricted HIV-1-specific cytotoxic T lymphocytes and escape mutation after ART with structured treatment interruptions

Microbes and Infection

Volumn 10, Issue 6, 2008, Pages 689-698

  Tanuma, Junko ^a   Fujiwara, Mamoru ^b   Teruya, Katsuji ^a   Matsuoka, Saori ^a   Yamanaka, Hikaru ^a   Gatanaga, Hiroyuki ^a   Tachikawa, Natsuo ^a   Kikuchi, Yoshimi ^a   Takiguchi, Masafumi ^b   Oka, Shinichi ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Cytotoxic T lymphocyte; Escape variant; HLA A*2402; Structured treatment interruptions

Indexed keywords

ANTIRETROVIRUS AGENT; EPITOPE; HLA A ANTIGEN; NEF PROTEIN; HLA A2402 ANTIGEN;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HLA TYPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; STRUCTURED TREATMENT INTERRUPTION; TREATMENT WITHDRAWAL; VIRUS LOAD; VIRUS MUTATION; BLOOD; CHEMISTRY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MUTATION; PROSPECTIVE STUDY; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-RETROVIRAL AGENTS; EPITOPES; HIV INFECTIONS; HIV-1; HLA-A ANTIGENS; HUMANS; MUTATION; PROSPECTIVE STUDIES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 44449095452     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2008.03.007     Document Type: Article

References (29)

1. Lisziewicz J., Rosenberg E.S., Lieberman J., Heiko J., Lopalco L., Siliciano R., Walker B., and Lori F. Control of HIV despite the discontinuation of antiretroviral therapy. N. Engl. J. Med. 340 (1999) 1683-1684
2. Rosenberg E.S., Altfeld M., Poon S.H., Phillips M.N., Wilkies B.M., Eldridge R.L., Robbins G.K., D'Aquila R.T., Goulder P.J.R., and Walker B.D. Immune control of HIV-1 after early treatment of acute infection. Nature 407 (2000) 523-526
3. Lori F., Lewis M.G., Xu J., Varga G., Zinn Jr. D.E., Crabbs C., Wagner W., Greenhouse J., Silvera P., Yalley-Ogunro J., Tinelli C., and Lisziewicz J. Control of SIV rebound through structured treatment interruptions during early infection. Science 290 (2000) 1591-1593
4. Lawrence J., Mayers D.L., Hullsiek K.H., Collins G., Abrams D.I., Reisler R.B., Crane L.R., Schmetter B.S., Dionne T.J., Saldanha J.M., Jones M.C., and Baxter J.D. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N. Engl. J. Med. 349 (2003) 837-846
5. Lafeuillade A., Poggi C., Hittinger G., Counillon E., and Emilie D. Predictors of plasma human immunodeficiency virus type 1 RNA control after discontinuation of highly active antiretroviral therapy initiated at acute infection combined with structured treatment interruptions and immune-based therapies. J. Infect. Dis. 188 (2003) 1426-1432
6. 3. J. Acquir. Immune. Defic. Syndr. 36 (2004) 791-799
7. Hoen B., Fournier I., Lacabaratz C., Burgard M., Charreau I., Chaix M.L., Molina J.M., Livrozet J.M., Venet A., Raffi F., Aboulker J.P., and Rouzioux C. Structured treatment interruptions in primary HIV-1 infection. The ANRS 100 PRIMSTOP Trial. J. Acquir. Immune. Defic. Syndr. 40 (2005) 307-316
8. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68 (1994) 6103-6110
9. Ogg G.S., Jin X., Bonhoeffer S., Dunbar P.R., Nowak M.A., Monard S., Segal J.P., Cao Y., Rowland-Jones S.L., Cerundolo V., Hurley A., Markowitz M., Ho D.D., Nixon D.F., and McMichael A.J. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279 (1998) 2103-2106
10. Hess C., Altfeld M., Thomas S.Y., Addo M.M., Rosenberg E.S., Allen T.M., Draenert R., Eldrige R.L., Luzen J.V., Stellbrink H.J., Walker B.D., and Luster A.D. HIV-1 specific CD8+T cells with an effector phenotype and control of viral replication. Lancet 363 (2004) 863-866
11. Rosenberg E.S., Billingsley J.M., Caliendo A.M., Boswell S.L., Sax P.E., Kalams S.A., and Walker B.D. Vigorous HIV-1-specific CD4+T cell responses associated with control of viremia. Science 278 (1997) 1447-1450
12. Smith D.E., Walker B.D., Cooper D.A., Rosenberg E.S., and Kaldor J.M. Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence?. AIDS 18 (2004) 709-718
13. Hecht F.M., Wang L., Collier A., Little S., Markowitz M., Margolick J., Kilby J.M., Daar E., Conway B., Holte S., and for the AIEDRP Network. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J. Infect. Dis. 194 (2006) 725-733
14. Tremblay C.L., Hicks J.L., Sutton L., Giguel F., Flynn T., Johnston M., Sax P.E., Walker B.D., Hirsh M.S., Rosenberg E.S., and D'Aquila R.T. Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection. AIDS 17 (2003) 1086-1089
15. Kaufmann D.E., Lichterfeld M., Altfeld M., Addo M.M., Johnston M.N., Lee P.K., Wagner B.S., Kalife E.T., Strick D., Rosenberg E.S., and Walker B.D. Limited durability of viral control following treated acute HIV infection. PLoS Med. 1 (2004) e36
16. Allen T.M., O'Connor D.H., Jing P., Dzuris J.L., Mothe B.R., Vogel T.U., Dunphy E., Lieble M.E., Emerson C., Wilson N., Kunstman K.J., Wang X., Allison D.B., Hughes A.L., Desrosiers R.C., Altman J.D., Wolinsky S.M., Sette A., and Watkins D.I. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407 (2000) 386-390
17. Evans D.T., O'Connor D.H., Jing P., Dzuris J.L., Sydney J., da Silva J., Allen T.M., Horton H., Venham J.E., Rudersdorf R.A., Vogel T., Pauze C.D., Bontrop R.E., DeMars R., Sette A., Hughes A.L., and Watkins D.I. Virus-specific cytotoxic T lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat. Med. 5 (1999) 1270-1276
18. Barouch D.H., Kunstman J., Kuroda M.J., Schmits J.E., Santra S., Peyerl F.W., Gorgone G.R., Montefiori D.C., Lewis M.G., Wolinsky S.M., and Letvin N.L. Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys. J. Virol. 77 (2003) 7367-7375
19. Moore C.B., John M., James I.R., Christriansen F.T., Witt C.S., and Mallal S.A. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296 (2002) 1439-1443
20. Goulder P.J., Brander C., Tang Y., Tremblay C.A., Colbert R.A., Addo M.M., Rosenberg E.S., Nguyen T., Allen R., Trocha A., Altfeld M., He S., Bunce M., Funkhouser R., Pelton S.I., Burchett S.K., McIntosh K., Korber B.T., and Walker B.D. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 412 (2001) 334-338
21. Furutsuki T., Hosoya N., Kawana-Tachikawa A., Tomizawa M., Odawara T., Goto M., Kitamura Y., Nakamura T., Kelleher A.D., Cooper D.A., and Iwamoto A. Frequent transmission of cytotoxic-T-lymphocyte escape mutants of human immunodeficiency virus type 1 in the highly HLA-A-24-positive Japanese population. J. Virol. 78 (2004) 8437-8445
22. Ikeda-Moore Y., Tomiyama H., Miwa K., Oka S., Iwamoto A., Kaneko Y., and Takiguchi M. Identification and characterization of multiple HLA-A24-restricted HIV-1 CTL epitopes: Strong epitopes are derived from V regions of HIV-1. J. Immunol. 159 (1997) 6242-6252
23. Fujiwara M., Tanuma J., Koizumi H., Kawashima Y., Honda K., Matsuoka-Aizawa S., Dohki S., Oka S., and Takiguchi M. Different abilities of escape mutant-specific cytotoxic T cells to suppress replication of escape mutant and wild-type human immunodeficiency virus type 1 in new hosts. J. Virol. 82 (2008) 138-147
24. Johnson V.A., Brun-Vezinet F., Clotet B., Kuritzkes D.R., Pillay D., Schapiro J.M., and Richman D.D. Update of the drug resistance mutations in HIV-1: Fall 2006. Top. HIV Med. 14 (2006) 125-130
25. Altman J.D., Moss P.A.H., Goulder P.J.R., Barouch D.H., McHeyzer-Williams M.G., Bell J.I., McMichael A.J., and Davis M.M. Phenotypic analysis of antigen-specific T lymphocytes. Science 274 (1996) 94-96
26. Carrington M., and O'Brien S.J. The influence of HLA genotype on AIDS. Annu. Rev. Med. 54 (2003) 535-551
27. Tomiyama H., Akari H., Adachi A., and Takiguchi M. Different effects of Nef-mediated HLA class I down-regulation on human immunodeficiency virus type 1-specific CD8+T-cell cytolytic activity and cytokine production. J. Virol. 76 (2002) 7535-7543
28. Tomiyama H., Fujiwara M., Oka S., and Takiguchi M. Epitope-dependent effect of Nef-mediated HLA class I down-regulation on ability of HIV-1-specific CTLs to suppress HIV-1 replication. J. Immunol. 174 (2005) 36-40
29. Yokomaku Y., Miura H., Tomiyama H., Kawana-Tachikawa A., Takiguchi M., Kojima A., Nagai Y., Iwamoto A., Matsuda Z., and Ariyoshi K. Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection. J. Virol. 78 (2004) 1324-1332